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Abstract: The transferrin (TfR) and epidermal growth factor receptors (EGFR) are known to be
overexpressed on the surface of a wide variety of tumor cells. Therefore, the peptides B6 (TfR
specific) and GE11 (targeted to the EGFR) were linked to the PAMAM (polyamidoamine) structure
via a polyethylenglycol (PEG) 2 kDa chain with the aim of improving the silencing capacity of
the PAMAM-based dendriplexes. The complexes showed an excellent binding capacity to the
siRNA with a maximal condensation at nitrogen/phosphate (N/P) 2. The nanoparticles formed
exhibited hydrodynamic diameters below 200 nm. The zeta potential was always positive, despite
the complexes containing the PEG chain in the structure showing a drop of the values due to the
shielding effect. The gene silencing capacity was assayed in HeLa and LS174T cells stably transfected
with the eGFPLuc cassette. The dendriplexes containing a specific anti luciferase siRNA, assayed at
different N/P ratios, were able to mediate a mean decrease of the luciferase expression values of 14%
for HeLa and 20% in LS174T cells, compared to an unspecific siRNA-control. (p < 0.05). In all the
conditions assayed, dendriplexes resulted to be non-toxic and viability was always above 75%.
Keywords: nanotechnology; cancer; gene therapy; cationic polymers; polyethylenglycol;
gene silencing
1. Introduction
During the last years, research has focused on the improvement of non-viral systems for gene
therapy. In order to achieve better vectors with enhanced gene delivery activity, different ligands
have been included in the formulations. The epidermal growth factor receptor (EGFR) and transferrin
receptor (TfR) are two of the most used targeted sites for specific delivery of nucleic acids, since they are
overexpressed on the surface of tumoral cells compared with healthy tissues and have demonstrated
good activity for drug and gene delivery [1].
The gene transfer capacity of targeted non-viral vectors and novel drug delivery systems including
specific ligands has proven to be effective in increasing internalization and delivery of the cargo
in vitro and in vivo [2]. However, the inclusion of large proteins in a formulation may result in
problems including synthesis procedures and stability; therefore, the necessity of smaller synthetic
ligands has increased. The peptides GE11 and B6 do not contain more than 15 amino acids and bind
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specifically the EGFR and TfR, respectively. B6, described by Xia et al. in a phage display library [3],
has been used for targeting L-polyethylenimine (LPEI) polyplexes [4], peptide-polyethylenglycol
(PEG)-oligo(ethaneamino)amides [5] and other polymeric systems [6,7]. In a similar way, GE11
peptide was described by Li et al. [8] and subsequently used for the targeting LPEI complexes and
other polymers [9,10] with similar results than the ones obtained by EGF protein even in vivo [9].
Concerning the use of these peptides with polyamidoamine (PAMAM) dendrimers, the main objective
has pursued the enhancement of the uptake and transfection rate of adenovirus electrostatically coated
with PAMAM-G2-PEG-GE11 [11–13].
The use of small interfering RNA (siRNA) has become an interesting tool for the specific
knockdown of disease-causing genes. A siRNA molecule is constituted by, approximately, 20 pairs
of highly specific bases, which are able to activate a complex cellular mechanism that leads to the
destruction of a messenger RNA (mRNA). This interaction will have as a consequence the knockdown
of the protein coded by the specific mRNA. So far, the use of siRNA in non-viral systems has
been based on the use of cationic polymers like polyethyleneimine and chitosan [14,15]. PAMAM
dendrimers are considered as an interesting alternative to other cationic polymers due to their low
cytotoxicity, controlled molecular weight, high charge density and versatility [16]. Nevertheless,
their use as an siRNA delivery system has been limited. Zhou et al. reported the ability of
non-degraded PAMAM dendrimers to form nanoparticles in the presence of RNA [17] and other
groups have tried to describe the binding mechanism between PAMAM and siRNA, as well as the
importance of the nitrogen/phosphate (N/P) ratio, ionic strength of the medium, the size and the
dendrimer generation on the complexes [18–20]. The activity of this family of molecules has also
been studied [21] and, as the presence of targeting is known to improve the activity of non-viral
vectors, RNA/dendriplexes have been targeted to the CD44 receptor [22], TfR [23] and EGFR [24].
At the same time, Tsutsumi et al. and Arima and coworkers have extensively studied the behavior
of PAMAM dendrimer/α-cyclodextrin conjugates [25–29], and Biswas et al. have improved the
behavior of the PAMAM dendrimer by generating a micellar formulation of PAMAM-PEG-DOPE
(dioleoylphosphatidylethanolamine)/siRNA complexes [30]. The different strategies adopted for
improving the siRNA delivery activity of PAMAM/siRNA complexes has been extensively reviewed
elsewhere [31,32].
For the first time, in this work we have evaluated the ability of PAMAM to form nanoparticles
in the presence of siRNA, and the gene silencing capacity and cytotoxicity of two new PAMAM
conjugates. These novel carriers are coupled to the specific peptides GE11 or B6 via a PEG 2 kDa
linker, which have previously been demonstrated to be effective in improving gene delivery in other
non-viral systems.
2. Materials and Methods
2.1. Materials
DMSO (dimethylsulfoxide purissimum), DTT (DL-Dithiothreitol) and TNBS (2,4,6-
trinitrobenzenesulfonic acid solution) were obtained from Sigma-Aldrich GmbH (Munich, Germany).
Water was used as purified, de-ionized water. NHS-PEG-OPSS (ω-2-pyridyldithio polyethylene
glycol α-succinimidylester, 2 kDa) was synthesized by Rapp Polymere GmbH (Tübingen, Germany).
Peptides GE11 (CYHWYGYTPQNVI-OH, TFA salt, >95% purity) and B6 (CGHKAKGPRK-OH, TFA
salt, >95% purity) by Biosyntan GmbH (Berlin, Germany). LPEI (22 kDa) was synthesized as described
by Schaffert et al. [33]. Amine terminated PAMAM dendrimer (Generation 5, 1,4-diaminobutane core,
molecular weight 28,854 Da) were purchased from Dendritic Nanotechnologies (Mount Pleasant, MI,
48858, USA). HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) was obtained from Biomol
GmbH (Hamburg, Germany). H-L-Cysteine from IRIS Biotech GmbH (Marktredwitz, Germany) and
MacroPrep High S from BioRad GmbH (Munich, Germany). Dialysis was performed with spectra/Por
membranes (molecular mass cut-off 10 kDa) from Spectrum Laboratories Inc. (Breda, The Netherlands).
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Cell culture 5× lysis buffer and D-Luciferin sodium salt were purchased from Promega (Mannheim,
Germany). Cell culture media, antibiotics, L-alanine-L-glutamine and non-essential aminoacids
(NEAA) were obtained from Biochrom (Berlin, Germany). Fetal calf serum was purchased from Gibco
(Life Technologies, Carlsbad, CA, USA).
2.2. Conjugate Synthesis
2.2.1. Synthesis of PAMAM-PEG(2 kDa)-OPSS
Synthesis of PAMAM-G2-PEG-OPSS was carried out in principle as described recently for
LPEI-PEG-OPSS [9] with some modifications. In brief, PAMAM G5 in EtOH was reacted with
NHS-PEG-OPSS (2 kDa) dissolved in DMSO for 3 h under agitation at 37 ◦C. Thereafter, 2 M HEPES
pH 7.4, 3 M NaCl and water were added to give a final concentration of 20 mM HEPES and 0.6 M NaCl
and pH adjusted to 7.4 using hydrochloric acid. The reaction mixture was loaded on a cation-exchange
column (Macro-prep High S; 10/10; BioRad, Munich, Germany) and fractionated with a salt gradient
from 0.6 to 3 M NaCl in 20 mM HEPES, pH 7.4. The product eluted between 2 and 2.6 M NaCl
and was dialyzed overnight at 4 ◦C against HBS (20 mM HEPES, 150 mM NaCl, pH 7.4) with a
Spectra/Por membrane (molecular mass cut-off 10 kDa). The PAMAM G5 content of the conjugate
was determined by TNBS assay, which is used for detection of primary amines. To ascertain the
quantity of linker coupled to the PAMAM G5, the amount of dithiopyridine after reduction of an
aliquot with DTT was evaluated by spectrophotometric measurement of released pyridine-2-thione
(ε343 = 8080 M−1 × mol−1). PAMAM G5-PEG-OPSS was synthesized at a final molar ratio of 1:1.1.
2.2.2. Synthesis of PAMAM-PEG(2 kDa)-OPSS
The peptides GE11 and B6 were added to PAMAM-PEG-OPSS. After 3 h incubation at room
temperature, the released thiopyridone was measured at 343 nm to determine the extent of peptide
conjugation. Removal of unreacted peptides was carried out on a Macroprep High S cationic-exchange
column (Bio-Scale MT 2, BioRad, Munich, Germany) as described previously. The amount of peptide
was calculated via the extinction coefficient at 280 nm (ε = 9970 M−1 × mol−1). The molar ratio of
PAMAM G5 to GE11 was 1:0.47 and 1:0.5 for B6.
2.2.3. Synthesis of PAMAM-PEG-Cys
PAMAM-PEG-Cys was synthesized by mixing one part of PAMAM G5-PEG-OPSS with four parts
of cysteine at ambient temperature. Purification was carried out on a gel-filtration column (Sephadex
G-25; HR10/30 Columns; 20 mM HEPES, pH 7.4) to remove piridine-2-thione and unreacted cysteine.
The molar ratio of PAMAM G5 to Cys was 1:1.1.
2.3. Preparation of PAMAM-PEG-Peptide/siRNA and LPEI/siRNA Complexes
In general, polyplexes were generated by condensing specific siRNA-luciferase (Luc) or
siRNA-Control with PAMAM or PAMAM conjugates at different N/P ratio of PAMAM nitrogen
to RNA phosphate. Therefore, PAMAM/siRNA polyplexes were prepared freshly at a final siRNA
concentration of 10 µg/mL in HEPES-buffered glucose (HBG 5% (w/w) glucose, 20 mM HEPES, pH
7.4) by mixing equal volumes of HBG containing the desired amount of siRNA and PAMAM or LPEI.
Dendriplexes and polyplexes were allowed to stand for at least 20 min at room temperature before use.
More precisely, regarding the DNA nanocomplexation, it should be pointed out that the ability of the
polycationic PAMAM polymer to complex the siRNA was previously demonstrated.
2.4. Particle Size and Zeta Potential Measurements
The particle size of dendrimer/siRNA formulations and zeta potentials were measured by
laser-light scattering using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). Polyplexes
J. Pers. Med. 2018, 8, 4 4 of 12
were prepared at a final concentration of 10 µg siRNA/mL in BHG and measured after 30 min
of incubation.
2.5. Ethidium Bromide Exclusion Assay
A Cary Eclipse spectrophotometer (Varian, Germany) was used for the quantification of ethidium
bromide (EtBr) fluorescence at the excitation wavelength λex = 510 nm and emission wavelength
λem = 590 nm. 1 mL HBG buffer containing 0.4 µg EtBr was used as blank. After addition of 10 µg
siRNA-Control the solution was incubated for 3 min and EtBr fluorescence was assigned to 100%.
Increasing amounts of PAMAM or PAMAM-PEG-Peptide corresponding to indicated N/P ratios were
added, incubated for 30 s and EtBr fluorescence was determined in relation to the 100% value.
2.6. Cell Culture
LS174T/eGFPLuc cell line (LS174T) (colorectal adenocarcinoma) was cultured in RPMI 1640 and
HeLa/eGFPLuc (HeLa) (cervix adenocarcinoma) cells were cultured in DMEM. Both cell lines were
stably transfected with the eGFPLuc gene cassette as described recently by Su et al. [34]. All cell
culture media was supplemented with 10% fetal calf serum, 100 units/mL penicillin, 100 µg/mL
streptomycin and 1% L-alanine-L-glutamine (200 mM). All cultured cells were grown at 37 ◦C in 5%
CO2 in humidified atmosphere. Cells were passed twice a week by trypsinization.
2.7. Gene Silencing Capacity
HeLa and LS174T cells were cultured as described before. For each experiment 104 cells were
seeded in 96 well plates 24 h before the treatment. Complexes containing specific siRNA-Luc or
siRNA-Control were freshly prepared at the indicated N/P ratios. 20 µL containing 200 ng of siRNA
and 80 µL of medium were added to each well and incubated for 4 h. After this time, transfection
medium was removed and substituted by 100 µL of fresh culture medium. After 48 h cells were rinsed
with PBS and treated with Lysis Buffer (Promega). 30 µL of the lysate were assayed with the Luciferase
Assay Kit (100 µL Luciferase Assay buffer, Promega) and a Centro LB 960 plate reader luminometer
(Berthold, Bad Wildbach, Germany). The relative light units (RLU) obtained were normalized and
presented as the percentage of expression compared to non-treated control cells.
2.8. Toxicity Studies
HeLa and LS174T cells were seeded into 96-well plates at a density of 104 cells/well. After 24 h,
culture medium was replaced with 80 µL fresh growth medium and 20 µL of transfection complexes.
4 h after, transfection medium was replaced by fresh medium. 48 h post transfection, 10 µL MTT
(5 mg/mL) were added to each well reaching a final concentration of 0.5 mg MTT/mL. After an
incubation time of 2 h, unreacted dye and medium were removed. The purple formazan product
was dissolved in 100 µL DMSO/well and quantified by a microplate reader (Spectrafluor Plus, Tecan
Austria GmbH, Grödig, Austria) at a 590 nm with background correction at 630 nm. The relative cell
viability (%) compared to control cells containing cells treated with HBG was calculated according to
the formula (A590 − A630) of treated cells × 100/(A590 − A630) of control cells.
2.9. Statistical Analysis
Results are reported as the mean values ± standard deviation. Statistical analysis was performed
with SPSS 15.0 (SPSS, Chicago, IL, USA). The different transfection activities in vitro were compared
with ANOVA (Tukey post-hoc adjust). Differences were considered statistically significant at p < 0.05.
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3. Results
3.1. Size and Zeta Potential Determination
Particle size and surface charge were measured in order to study the influence of the N/P ratio
and the presence of the different ligands (Table 1).
Table 1. Particle size and surface charge in the presence or absence of ligands and different N/P ratios.
The data are represented as the mean ± SD (standard deviation) of three measurements.
N/P Size PDI ZP
PAMAM-G5 (PLAIN)
2 109.1 ± 0.8 0.15 32.1 ± 1.1
4 114.7 ± 0.7 0.16 37.6 ± 0.3
6 122.6 ± 0.9 0.17 40.0 ± 1.0
GE11
2 106.6 ± 0.3 0.09 23.0 ± 2.0
4 105.7 ± 0.8 0.17 27.4 ± 0.5
6 107.5 ± 1.1 0.23 27.7 ± 1.8
B6
2 71.2 ± 1.0 0.12 23.5 ± 0.9
4 75.5 ± 0.8 0.21 20.3 ± 0.6
6 n.d. n.d. n.d.
Cys
2 103.0 ± 3.0 0.24 21.1 ± 1.1
4 125.0 ± 29.0 0.37 25.4 ± 1.1
6 199.3 ± 19.7 0.51 26.0 ± 2.0
PAMAM: polyamidoamine, N/P: nitrogen/phosphate ratio, PDI: polydispersion index, ZP: zeta potential
Size measurements were performed by dynamic light scattering. As shown in Table 1, particle
size was always below 200 nm, presenting an excellent hydrodynamic diameter independently of the
N/P ratio used. The presence of the ligand seemed to have little effect on the particle size. Plain and
GE11-containing conjugates presented similar sizes and PAMAM-PEG-B6 complexes exhibited the
smallest sizes, whereas PAMAM-PEG-Cys presented increased diameters and high polydispersity
index (PDI). The other formulations showed PDI values below 0.3.
Surface charge was always positive, with zeta potential values above 20 mV in all the cases.
The formulation of the dendriplexes with PAMAM conjugates containing a PEG 2 kDa chain produced
nanoparticles with lower zeta potential compared to plain dendriplexes, independently of the N/P
ratio used. The presence of the targeting peptide did not influence the zeta potential results.
3.2. Ethidium Bromide Exclusion Assay
The interaction between PAMAM dendrimers and siRNA was evaluated by the ability of
dendrimers to displace the intercalating dye, ethidium bromide, from the siRNA. As shown in Figure 1,
as the charge ratio of the complexes increased, the relative fluorescence decreased to a maximum
binding degree at N/P ratio 2. The formulation of the dendriplexes with PEG linked peptides did not
produce any difference in the behavior of the complexes and similar profiles were obtained.
Figure 1. Condensation assay: siRNA condensation measured as a decrease in fluorescence of EtBr
added to dendriplexes.
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3.3. Toxicity Studies
For all the dendriplexes tested in this work and for all the N/P ratios, MTT assay was performed
(Figure 2). Viability values of dendriplexes were always above 75% in HeLa and LS174T cells. LPEI
polyplexes exhibited similar viability values to those obtained for dendriplexes in HeLa, whereas
in LS174 cells LPEI treatment lead to a drop of viability values below 60% compared to non-treated
cells. Between LPEI polyplexes containing specific siRNA-Luc and siRNA-control in HeLa cells,
similar values were obtained; however, in LS174T cells, LPEI polyplexes containing specific siRNA-Luc
resulted to be more toxic than PAMAM-dendriplexes, resulting a drop in the viability to 25%.
Figure 2. Viability of HeLa and LS174T cells. LPEI (polyethylenimine) polyplexes, PAMAM-plain and
targeted PAMAM conjugates with specific siRNA-Luc or siRNA-Control were applied at different N/P
ratios. Non-treated cells were included as control. Data are expressed as the mean ± SD (n = 4).
3.4. Gene Silencing Efficacy
In order to explore the blockage of the luciferase expression in two cell lines stably transfected
with the cassette eGFPLuc, a specific siRNA (siRNA-Luc) was used in order to block the expression
and unspecific siRNA (siRNA-control) was used as a control.
In HeLa cell line (Figure 3), the treatment with siRNA-control produced a decrease in the
expression of approximately 20% for all the dendriplexes assayed compared to non-treated cells.
The inhibition mediated by the specific siRNA-Luc carrying dendriplexes, compared to control
cells, was slightly higher and statistically significant at N/P 4 and 6 ratios. This drop, compared
to siRNA-control, represented a mean decrease of 14% of the luciferase expression values (p < 0.05).
The inclusion of the different ligands was not able to produce differences in any case compared to
plain dendriplexes and Cys conjugate containing dendriplexes. LPEI polyplexes carrying specific
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siRNA-Luc were able to generate a statistically significant decrease in luciferase expression values
compared to non-treated cells and the siRNA-Control containing LPEI polyplexes.
Figure 3. Luciferase silencing efficacy of PAMAM-G5 (Plain) and PAMAM-PEG-GE11/B6/Cys
dendriplexes with specific siRNA-Luc or siRNA-control complexes prepared at various N/P ratios.
Provided data represent the percentage of expression compared to non-treated (control) cells. Data are
expressed as the mean ± SD (n = 8). Differences were considered statistically different at p < 0.05.
Gene silencing efficacy was also assayed in LS174 cell line (Figure 3), where control-siRNA
containing dendriplexes produce an average drop of 5% of the luciferase expression values. The mean
decrease of the siRNA-Luc containing dendriplexes was around 20% compared to siRNA-control.
The inclusion of targeted dendrimers did not produce any difference in the inhibitory activity of
the dendriplexes compared to non-targeted ones. LPEI polyplexes were able to mediate an effective
decrease of the luciferase values; however, comparing the effect of the specific siRNA-Luc with
siRNA-control, the difference was not statistically significant.
4. Discussion
One of the main problems to be overcome concerning the use of non-viral systems is the low
efficiency and selectivity. The TfR is known to be overexpressed in a variety of tumor cells, as
well as the EGFR receptor. Therefore, these receptors are an interesting target for gene therapy
improvement. As Scholz et al. claims, the presence of big proteins can lead to problems during
synthesis and storage [15]. In order to solve this drawback, the peptides B6 and GE11, specific for
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the TfR and EGFR respectively, were selected as the targeting moieties to improve the activity of the
PAMAM/siRNA dendriplexes.
The size and zeta potential measurements confirmed that the PAMAM dendrimer and
PAMAM-PEG-peptide conjugates were able to form nanoparticles with positive surface charge (Table 1).
Apparently, significant differences in size could not be described between the plain dendriplexes and
the targeted ones, although PAMAM-PEG-B6 containing dendriplexes presented slightly smaller sizes,
which could be related with the cationic nature of the B6 ligand. On the other hand, PAMAM-PEG-Cys
complexes showed the highest hydrodynamic diameter and PDI. Zeta potential values exhibited a
clear drop comparing plain to targeted conjugates. The presence of the linker PEG 2 kDa is likely to be
the reason of this variation since the PAMAM-PEG-Cys conjugate containing dendriplexes, which do
not contain a peptide in their structure, also present this tendency. In agreement with previous data,
the PEG 2 kDa chain produced a decrease in the zeta potential values but did not lead to completely
charge neutral particles in LPEI based polyplexes [4,9]. Moreover, it is known that PEG can shield the
surface charge of the complexes [35].
One aspect to be considered during the optimization of these kinds of complexes is the importance
of the polymer flexibility. In this respect, as siRNA strands contain only up to 20–25 pairs of bases,
the structure of the polymer plays an important role during coupling and gene silencing. Kwok et al.
studied the stability of LPEI and bPEI siRNA polyplexes, concluding that bPEI showed a better
behavior, due to its more flexible branched structure [36]. More flexible PAMAM dendrimers have
reported to improve the activity in gene delivery [37]. This approach has been adapted and bigger
initial cores of the molecule have been selected with good results [17]. In this study, the PAMAM
structure presents a 1,4-diaminobutane instead of the ethylenediamine core used for pDNA delivery
previously used in this work, which can provide higher flexibility to the dendrimer. Subsequently, to
ensure the formation of a complex, in which the RNA was tightly condensed, an ethidium bromide
exclusion assay was performed (Figure 1). The results showed that plain dendriplexes were able to
efficiently bind and condense RNA at N/P 2 and higher ratios. The presence of the peptide or the
PEG 2 kDa chain did not produce any disturbance of the behavior. These data are in agreement with
previous results, which reported that PEG with this molecular weight produces a decrease of the
surface charge but it did not negatively influence the DNA condensation of LPEI-PEG-GE11/DNA
complexes [9].
The activity of the new conjugates was assayed in modified HeLa and LS174T cell lines stably
transfected with the eGFPLuc cassette (Figure 3). The silencing effect of the unspecific siRNA
used as control was negligible. When a specific siRNA-Luc was used, the expression values drop
by 14% and 20% on average in HeLa and LS174T cells, respectively, compared to the unspecific
siRNA-control (p < 0.05). The PAMAM-PEG-Cys conjugate did not produce any significant variation
of the silencing activity of the complexes compared to the plain dendriplexes and the silencing efficacy
was in the same range. Similarly, the conjugation with the specific peptides B6 and GE11 did not
produce an improvement of the inhibitory activity of the dendriplexes compared to non-targeted
dendriplexes. This lack of improvement, compared to plain dendriplexes, can be partially explained
by the presence of PEG, as this molecule is known to reduce the gene delivery activity of different
formulations [35,38]. Schafer et al. explored the possibility of targeting LPEI conjugated with the GE11
peptide (LPEI-PEG-GE11/pDNA complexes). In U-87 MG cells, the LPEI-GE11 conjugate was not
able to produce higher transfection values compared to non-targeted polyplexes. As they claim, the
detargeting can be related with the reduced surface charge or the influence of bulky molecules on
the endosomal release [9]. Similar results have been reported by Nie et al. using the peptide B6 as a
targeting agent in LPEI-PEG-B6/pDNA based polyplexes. Transfection values in PC3 cells were in a
similar range compared to the non-targeted control, nevertheless, the B6 containing polyplexes were
able to enhance the cellular association [4]. The siRNA molecule has reached their place of action once in
the cytosol and an early release from the endosome is highly desired [15]. The TfR and EGFR-mediated
endocytosis are known to imply degradation processes at some extent [39]. At this respect, Martin et al.
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were able to enhance the transfection activity of B6 peptide-PEG-oligo(ethane-amino)amides only
by the presence of chloroquine or other endosomolytic agents [5]. Therefore, if the presence of the
PEG chain may block the endosomal release, and a lytic pathway is favored by the presence of the
ligand, the proton sponge mechanism of the PAMAM dendrimer structure could not be enough for
promoting the rupture of the vesicles and the lack of improvement in gene silencing efficacy could be
partially expected.
Despite the fact that the use of these peptides has not been explored with PAMAM dendrimers in
gene delivery, Vetter et al. studied the ability of the GE11 peptide to enhance the transfection activity of
adenovirus type 5 (Ad) and to achieve a targeted expression in EGFR positive tumors with the binding
of Ad to PAMAM-PEG-GE11 conjugates [13]. They compared the PAMAM-G5-PEG-GE11 conjugates
with the PAMAM-G2 ones and concluded that PAMAM-G5 was less efficient in terms of targeting
compared to G2. The different molecular weight and coupling rate, as well as the necessity of a
cooperative binding of several GE11 peptides are the explanations they suggest for this difference [13].
In this respect, the peptide to dendrimer molar ratio should be optimized and new chemical syntheses
carried out to modify this ratio. In close relation with the amount of the ligand, the presence of the
receptor can play an important role in the gene silencing process. The overexpression of the TfR and
EGFR was described in the literature. HeLa cell line has been reported to present high amounts of
TfR on its surface [40] as well as EGFR [41,42], similarly LS174T cell line is considered as positive for
both receptors [43–45]. It is known that the receptor expression varies from one cell batch to another
and, hence, differences in the endocytic processes may be expected. Moreover, it is known that each
cell line brings a specific behavior with each complex [46]. Because of that, the pr, sence of the specific
receptor must be ensured to correlate the behavior of the conjugates.
As expected, the viability values of the targeted complexes were similar to those produced by the
non-targeted dendriplexes and were always above 75% (Figure 2). As a consequence, the silencing
effect of the treatment with siRNA-Luc dendriplexes must be mediated by the siRNA-Luc specific
inhibition. Control LPEI polyplexes resulted to be toxic in LS174T cells, reducing the viability values
to 25%, whereas in HeLa cells viability was similar compared to dendriplexes.
The excellent results provided by the toxicity assays make these vectors suitable for further
improvement. Moreover, the interesting shielding effect of the PEG chain included can partially
explain the lack of improvement in the gene silencing profile, without eradicating the possibility of
using this conjugates for in vivo purposes, since the extrapolation from in vitro results to in vivo is
still limited for these systems.
5. Conclusions
In this work, two novel PAMAM-PEG 2 kDa-peptides conjugates targeted to the TfR and EGFR
have been evaluated. The presence of the peptides B6 and GE11 did not produce any variation in
the size and zeta potential values, presenting always a nanometric size and positive zeta potential
values. The presence of the PEG chain produced a decrease in the surface charge, but the condensing
ability was not negatively influenced, as shown by the ethidium bromide assay. The gene silencing
capacity mediated by a siRNA-control was negligible; meanwhile, the use of a specific siRNA-Luc was
able to reduce luciferase expression a 14% and 20% on average in HeLa and LS174 cells, respectively,
compared to siRNA-control (p < 0.05). The presence of the peptides did not improve the gene silencing
activity compared to plain dendriplexes. Toxicity studies confirmed the low toxicity of the PAMAM
dendrimer conjugates, meanwhile LPEI polyplexes resulted to be highly toxic in the LS174T cell line.
Acknowledgments: This work was financially supported by the Government of Navarra (Department of
Innovation and Industry) (Ref. IIQ14334.RI1), the FEDER fundings from the European Commission and the
University of Navarra Foundation (FUN).
Author Contributions: M.O. designed experiments and provided material. K.U. and L.B.-F characterized the
complexes, W.R. synthetised the conjugated plasmids, C.T.I. and E.W. conducted the article.
Conflicts of Interest: The authors declare no conflict of interest.
J. Pers. Med. 2018, 8, 4 10 of 12
References
1. Schaffer, D.V.; Lauffenburger, D.A. Targeted synthetic gene delivery vectors. Curr. Opin. Mol. Ther. 2000, 2,
155–161. [PubMed]
2. Daniels, T.R.; Bernabeu, E.; Rodríguez, J.A.; Patel, S.; Kozman, M.; Chiappetta, D.A.; Holler, E.;
Ljubimova, J.Y.; Helguera, G.; Penichet, M.L. The transferrin receptor and the targeted delivery of therapeutic
agents against cancer. Biochim. Biophys. Acta 2012, 1820, 291–317. [CrossRef] [PubMed]
3. Xia, H.; Anderson, B.; Mao, Q.; Davidson, B.L. Recombinant human adenovirus: Targeting to the human
transferrin receptor improves gene transfer to brain microcapillary endothelium. J. Virol. 2000, 74,
11359–11366. [CrossRef] [PubMed]
4. Urnauer, S.; Klutz, K.; Grünwald, G.K.; Morys, S.; Schwenk, N.; Zach, C.; Gildehaus, F.J.; Roedl, W.; Ogris, M.;
Wagner, E.; et al. Systemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular
carcinoma mediated by B6 peptide polyplexes. J. Gene Med. 2017, 19. [CrossRef] [PubMed]
5. Martin, I.; Dohmen, C.; Mas-Moruno, C.; Troiber, C.; Kos, P.; Schaffert, D.; Lächelt, U.; Teixidó, M.;
Günther, M.; Kessler, H.; et al. Solid-phase-assisted synthesis of targeting peptide-PEG-oligo(ethane
amino)amides for receptor-mediated gene delivery. Organ. Biomol. Chem. 2012, 10, 3258–3268. [CrossRef]
[PubMed]
6. Lächelt, U.; Kos, P.; Mickler, F.M.; Herrmann, A.; Salcher, E.E.; Rödl, W.; Badgujar, N.; Bräuchle, C.; Wagner, E.
Fine-tuning of proton sponges by precise diaminoethanes and histidines in pDNA polyplexes. Nanomedicine
2014, 10, 35–44. [CrossRef] [PubMed]
7. Liu, Z.; Gao, X.; Kang, T.; Jiang, M.; Miao, D.; Gu, G.; Hu, Q.; Song, Q.; Yao, L.; Tu, Y.; et al.
B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide.
Bioconj. Chem. 2013, 24, 997–1007. [CrossRef] [PubMed]
8. Li, Z.; Zhao, R.; Wu, X.; Sun, Y.; Yao, M.; Li, J.; Xu, Y.; Gu, J. Identification and characterization of a novel
peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005, 19,
1978–1985. [CrossRef] [PubMed]
9. Schäfer, A.; Pahnke, A.; Schaffert, D.; Van Weerden, W.M.; De Ridder, C.M.; Rödl, W.; Vetter, A.; Spitzweg, C.;
Kraaij, R.; Wagner, E.; et al. Disconnecting the yin and yang relation of epidermal growth factor receptor
(EGFR)-mediated delivery: A fully synthetic, EGFR-targeted gene transfer system avoiding receptor
activation. Hum. Gene Ther. 2011, 22, 1463–1473. [CrossRef] [PubMed]
10. Ren, H.; Zhou, L.; Liu, M.; Lu, W.; Gao, C. Peptide GE11-Polyethylene Glycol-polyethylenimine for targeted
gene delivery in laryngeal cancer. Med. Oncol. 2015, 32, 185. [CrossRef] [PubMed]
11. Klutz, K.; Willhauck, M.J.; Wunderlich, N.; Zach, C.; Anton, M.; Senekowitsch-Schmidtke, R.; Göke, B.;
Spitzweg, C. Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer
after transcriptionally targeted intratumoral in vivo NIS gene delivery. Hum. Gene Ther. 2011, 22, 1403–1412.
[CrossRef] [PubMed]
12. Grünwald, G.K.; Klutz, K.; Willhauck, M.J.; Schwenk, N.; Senekowitsch-Schmidtke, R.; Schwaiger, M.;
Zach, C.; Göke, B.; Holm, P.S.; Spitzweg, C.; et al. Sodium iodide symporter (NIS)-mediated radiovirotherapy
of hepatocellular cancer using a conditionally replicating adenovirus. Gene Ther. 2013, 20, 625–633. [CrossRef]
[PubMed]
13. Vetter, A.; Virdi, K.S.; Espenlaub, S.; Rödl, W.; Wagner, E.; Holm, P.S.; Scheu, C.; Kreppel, F.; Spitzweg, C.;
Ogris, M.; et al. Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent
virus uptake and targeting to the EGF receptor. Mol. Pharm. 2013, 10, 606–618. [CrossRef] [PubMed]
14. Wang, J.; Lu, Z.; Wientjes, M.G.; Au, J.L. Delivery of siRNA therapeutics: Barriers and carriers. AAPS J. 2010,
12, 492–503. [CrossRef] [PubMed]
15. Scholz, C.; Wagner, E. Therapeutic plasmid DNA versus siRNA delivery: Common and different tasks for
synthetic carriers. J. Control. Release 2012, 161, 554–565. [CrossRef] [PubMed]
16. Mintzer, M.A.; Grinstaff, M.W. Biomedical applications of dendrimers: A tutorial. Chem. Soc. Rev. 2011, 40,
173–190. [CrossRef] [PubMed]
17. Zhou, J.; Wu, J.; Hafdi, N.; Behr, J.P.; Erbacher, P.; Peng, L. PAMAM dendrimers for efficient siRNA delivery
and potent gene silencing. Chem. Commun. 2006, 22, 2362–2364. [CrossRef] [PubMed]
J. Pers. Med. 2018, 8, 4 11 of 12
18. Shen, X.C.; Zhou, J.; Liu, X.; Wu, J.; Qu, F.; Zhang, Z.L.; Pang, D.W.; Quéléver, G.; Zhang, C.C.; Peng, L.; et al.
Importance of size-to-charge ratio in construction of stable and uniform nanoscale RNA/dendrimer
complexes. Organ. Biomol. Chem. 2007, 5, 3674–3681. [CrossRef] [PubMed]
19. Perez, A.P.; Romero, E.L.; Morilla, M.J. Ethylendiamine core PAMAM dendrimers/siRNA complexes as
in vitro silencing agents. Int. J. Pharm. 2009, 380, 189–200. [CrossRef] [PubMed]
20. Jensen, L.B.; Pavan, G.M.; Kasimova, M.R.; Rutherford, S.; Danani, A.; Nielsen, H.M.; Foged, C. Elucidating
the molecular mechanism of PAMAM-siRNA dendriplex self-assembly: Effect of dendrimer charge density.
Int. J. Pharm. 2011, 416, 410–418. [CrossRef] [PubMed]
21. Liu, X.; Liu, C.; Laurini, E.; Posocco, P.; Pricl, S.; Qu, F.; Rocchi, P.; Peng, L. Efficient delivery of sticky siRNA
and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM
dendrimer. Mol. Pharm. 2012, 9, 470–481. [CrossRef] [PubMed]
22. Han, M.; Lv, Q.; Tang, X.J.; Hu, Y.L.; Xu, D.H.; Li, F.Z.; Liang, W.Q.; Gao, J.Q. Overcoming drug resistance
of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a
novel siRNA polyamidoamine-hyaluronic acid complex. J. Control. Release 2012, 163, 136–144. [CrossRef]
[PubMed]
23. Kuang, Y.; An, S.; Guo, Y.; Huang, S.; Shao, K.; Liu, Y.; Li, J.; Ma, H.; Jiang, C. T7 peptide-functionalized
nanoparticles utilizing RNA interference for glioma dual targeting. Int. J. Pharm. 2013, 454, 11–20. [CrossRef]
[PubMed]
24. Yuan, Q.; Lee, E.; Yeudall, W.A.; Yang, H. Dendrimer-triglycine-EGF nanoparticles for tumor imaging and
targeted nucleic acid and drug delivery. Oral Oncol. 2010, 46, 698–704. [CrossRef] [PubMed]
25. Tsutsumi, T.; Hirayama, F.; Uekama, K.; Arima, H. Evaluation of polyamidoamine
dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering
RNA (siRNA). J. Control. Release 2007, 119, 349–359. [CrossRef] [PubMed]
26. Tsutsumi, T.; Hirayama, F.; Uekama, K.; Arima, H. Potential use of polyamidoamine
dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for short hairpin
RNA-expressing plasmid DNA. J. Pharm. Sci. 2008, 97, 3022–3034. [CrossRef] [PubMed]
27. Arima, H.; Tsutsumi, T.; Yoshimatsu, A.; Ikeda, H.; Motoyama, K.; Higashi, T.; Hirayama, F.; Uekama, K.
Inhibitory effect of siRNA complexes with polyamidoamine dendrimer/alpha-cyclodextrin conjugate
(generation 3, G3) on endogenous gene expression. Eur. J. Pharm. Sci. 2011, 44, 375–384. [CrossRef]
[PubMed]
28. Arima, H.; Yoshimatsu, A.; Ikeda, H.; Ohyama, A.; Motoyama, K.; Higashi, T.; Tsuchiya, A.; Niidome, T.;
Katayama, Y.; Hattori, K.; et al. Folate-PEG-appended dendrimer conjugate with alpha-cyclodextrin as a
novel cancer cell-selective siRNA delivery carrier. Mol. Pharm. 2012, 9, 2591–2604. [CrossRef] [PubMed]
29. Arima, H.; Motoyama, K.; Higashi, T. Polyamidoamine dendrimer conjugates with cyclodextrins as novel
carriers for DNA, shRNA and siRNA. Pharmaceutics 2012, 4, 130–148. [CrossRef] [PubMed]
30. Biswas, S.; Deshpande, P.P.; Navarro, G.; Dodwadkar, N.S.; Torchilin, V.P. Lipid modified triblock
PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials 2013, 34, 1289–1301. [CrossRef]
[PubMed]
31. Wu, J.; Huang, W.; He, Z. Dendrimers as carriers for siRNA delivery and gene silencing: A review. Sci.
World J. 2013, 630–654. [CrossRef] [PubMed]
32. Liu, X.; Rocchic, P.; Peng, L. Dendrimers as non-viral vectors for siRNA delivery. New J. Chem. 2011, 36,
256–263. [CrossRef]
33. Schaffert, D.; Kiss, M.; Rödl, W.; Shir, A.; Levitzki, A.; Ogris, M.; Wagner, E. Poly(I:C)-mediated tumor growth
suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine
as carrier. Pharm. Res. 2011, 28, 731–741. [CrossRef] [PubMed]
34. Su, B.; Cengiceroglu, A.; Farkasova, K.; Viola, J.R.; Anton, M.; Ellwart, J.W.; Haase, R.; Wagner, E.; Ogris, M.
Systemic TNF-α gene therapy synergizes with liposomal doxorubicine in the treatment of metastatic cancer.
Mol. Ther. 2013, 21, 300–308. [CrossRef] [PubMed]
35. Choe, J.H.; Choe, J.S.; Seo, H.R.; Park, J.S. Effect of Poly(ethylene glycol) Grafting on Polyethylenimine as a
Gene Transfer Vector in vitro. Bull. Korean Chem. Soc. 2001, 22, 46–52.
36. Kwok, A.; Hart, S.L. Comparative structural and functional studies of nanoparticle formulations for DNA
and siRNA delivery. Nanomedicine 2011, 7, 210–219. [CrossRef] [PubMed]
J. Pers. Med. 2018, 8, 4 12 of 12
37. Tang, M.X.; Redemann, C.T.; Szoka, F.C., Jr. In vitro gene delivery by degraded polyamidoamine dendrimers.
Bioconj. Chem. 1996, 7, 703–714. [CrossRef] [PubMed]
38. Li, W.; Szoka, F.C. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res. 2007, 24, 438–449.
[CrossRef] [PubMed]
39. Tortorella, S.; Karagiannis, T.C. Transferrin receptor-mediated endocytosis: A useful target for cancer therapy.
J. Membr. Biol. 2014, 247, 291–307. [CrossRef] [PubMed]
40. Sakaguchi, N.; Kojima, C.; Harada, A.; Koiwai, K.; Emi, N.; Kono, K. Effect of transferrin as a ligand of
pH-sensitive fusogenic liposome-lipoplex hybrid complexes. Bioconj. Chem. 2008, 19, 1588–1595. [CrossRef]
[PubMed]
41. Eiblmaier, M.; Meyer, L.A.; Watson, M.A.; Fracasso, P.M.; Pike, L.J.; Anderson, C.J. Correlating EGFR
expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical
cancer cell lines. J. Nucl. Med. 2008, 49, 1472–1479. [CrossRef] [PubMed]
42. Yu, C.; Hale, J.; Ritchie, K.; Prasad, N.K.; Irudayaraj, J. Receptor overexpression or inhibition alters cell surface
dynamics of EGF-EGFR interaction: New insights from real-time single molecule analysis. Biochem. Biophys.
Res. Commun. 2009, 378, 376–382. [CrossRef] [PubMed]
43. Aloj, L.; Jagoda, E.; Lang, L.; Caraco, C. Targeting of transferrin receptors in nude mice bearing A431 and
LS174T xenografts with [18F]holo-transferrin: Permeability and receptor dependence. J. Nucl. Med. 1999, 40,
1547–1555. [PubMed]
44. Crépin, R.; Goenaga, A.L.; Jullienne, B.; Bougherara, H.; Legay, C.; Benihoud, K.; Marks, J.D.; Poul, M.A.
Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the
growth of leukemias and lymphomas. Cancer Res. 2010, 70, 5497–5506. [CrossRef] [PubMed]
45. Milenic, D.E.; Wong, K.J.; Baidoo, K.E.; Ray, G.L.; Garmestani, K.; Williams, M.; Brechbiel, M.W.
Cetuximab: Preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and
radioimmunotherapeutic applications. Cancer Biother. Radiopharm. 2008, 23, 619–631. [CrossRef] [PubMed]
46. Von Gersdorff, K.; Sanders, N.N.; Vandenbroucke, R.; De Smedt, S.C.; Wagner, E.; Ogris, M.
The internalization route resulting in successful gene expression depends on both cell line and
polyethylenimine polyplex type. Mol. Ther. 2006, 14, 745–753. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
